↓ Skip to main content

Trastuzumab containing regimens for early breast cancer

Overview of attention for article published in Cochrane database of systematic reviews, April 2012
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
5 news outlets
blogs
2 blogs
twitter
58 tweeters
facebook
3 Facebook pages
wikipedia
1 Wikipedia page
googleplus
1 Google+ user

Citations

dimensions_citation
301 Dimensions

Readers on

mendeley
1 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Trastuzumab containing regimens for early breast cancer
Published in
Cochrane database of systematic reviews, April 2012
DOI 10.1002/14651858.cd006243.pub2
Pubmed ID
Authors

Lorenzo Moja, Ludovica Tagliabue, Sara Balduzzi, Elena Parmelli, Vanna Pistotti, Valentina Guarneri, Roberto D'Amico

Abstract

Approximately one-fifth of women who develop early breast cancer have HER2-positive tumours, which if untreated, have a worse prognosis than HER2-negative tumours. Trastuzumab is a selective treatment targeting the HER2 pathway. Although the results on efficacy seem to support its use, there are potential cardiac toxicities which need to be considered, especially for women at lower risk of recurrence, or those at increased cardiovascular risk.

Twitter Demographics

The data shown below were collected from the profiles of 58 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 1 Mendeley reader of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 3 300%
Portugal 2 200%
Korea, Republic of 2 200%
United States 2 200%
Sudan 1 100%
Brazil 1 100%
United Kingdom 1 100%
Austria 1 100%
Chile 1 100%
Other 2 200%

Demographic breakdown

Readers by professional status Count As %
Student > Master 38 3800%
Student > Bachelor 37 3700%
Researcher 36 3600%
Student > Ph. D. Student 33 3300%
Unspecified 26 2600%
Other 75 7500%
Readers by discipline Count As %
Medicine and Dentistry 124 12400%
Unspecified 43 4300%
Agricultural and Biological Sciences 24 2400%
Biochemistry, Genetics and Molecular Biology 17 1700%
Pharmacology, Toxicology and Pharmaceutical Science 9 900%
Other 28 2800%

Attention Score in Context

This research output has an Altmetric Attention Score of 92. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 August 2016.
All research outputs
#176,074
of 13,512,829 outputs
Outputs from Cochrane database of systematic reviews
#400
of 10,620 outputs
Outputs of similar age
#1,047
of 121,377 outputs
Outputs of similar age from Cochrane database of systematic reviews
#1
of 99 outputs
Altmetric has tracked 13,512,829 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,620 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 121,377 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 99 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.